Health
Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)
BOSTON, May 04, 2026--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, presented new findings at Digestive Diseases Week® (DDW) 2026 from a survey assessing healthcare provider (HCP) perspectives on the use of total parenteral nutrition (TPN) in the treatment of short bowel syndrome (SBS). Surveyed HCPs emphasized the importance of reducing patient dependen
About this update from Ironwood Pharmaceuticals, Inc.
[{"type":"text","content":"– Surveyed HCPs identified reduction of days on TPN as a top priority –","length":71,"tagName":"p","attribs":{}},{"type":"text","content":"– Improved quality of life, lower risk of infection and thrombosis viewed as key benefits of reduced TPN dependence –","length":117,"tagName":"p","attribs":{}},{"type":"text","content":"– Additional presentations feature long-term apraglutide safety and tolerability data, new linaclotide data analyses across patient populations –","length":145,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON, May 04, 2026--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, presented new findings at Digestive Diseases Week® (DDW) 2026 from a survey assessing healthcare provider (HCP) perspectives on the use of total parenteral nutrition (TPN) in the treatment of short bowel syndrome (SBS). Surveyed HCPs emphasized the importance of reducing patient dependence on TPN to improve quality of life, reduce line infections and lower the risk of thrombosis. The majority (46.4%) identified reducing the number of days per week on TPN as a priority attribute of future therapies. An additional 30.1% prioritized reducing TPN hours per day, while fewer respondents (11.3%) prioritized reducing TPN volume.","length":857,"tagName":"p"},{"type":"text","content":"SBS is a serious and chronic condition characterized by reduced absorptive capacity for fluids and/or nutrients, often requiring long-term dependence on parenteral support or PS (IV nutrition and/or IV hydration) to sustain life. Patients with SBS who are chronically dependent on PS, also referred to as SBS with intestinal failure (SBS-IF), frequently experience significant treatment burden, reduced quality of life and increased risk of severe complications such as infections. Despite current management approaches, substantial unmet need remains for therapies that reduce PS dependence and improve outcomes. An estimated 18,000 adult patients suffer from SBS-IF in the U.S., Europe and Japan, and have chronic dependence on PS.","length":733,"tagName":"p"},{"type":"text","content":""For many people living with short bowel syndrome, TPN is life-sustaining but can also profoundly affect quality of life. Th...